This LSD-Based Drug Just Scored Again. Definium Stock Soars.

Definium Therapeutics recently announced the successful completion of the second out of two favorable Phase 3 trials for its LSD-derived medication. Following this news, the biotech company's stock saw a significant increase in value. This achievement marks a significant turning point for the company and has generated positive attention from investors.